Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Identifying and applying molecular subgrouping in colorectal cancer

Share :

WIN Symposium 2013

10 - 12 Jul 2013
Published: 18 Jul 2013
Views: 5423
Rating:
Save
Dr Sabine Tejpar - University of Leuven, Leuven, Belgium

Dr Sabine Tejpar talks to ecancer that 2013 WIN Symposium about understanding the patterns for treating colorectal cancer and drug development, including novel agents.

 

Filmed in Partnership with the WIN Consortium

Related Videos

Addition of trastuzumab to chemo does not provide significant survival benefit in HER-2 positive stomach cancer

Dr Anna Dorothea Wagner - Lausanne University Hospital, Lausanne, Switzerland
Addition of trastuzumab to chemo does not provide significant survival benefit in HER-2 positive stomach cancer ( Dr Anna Dorothea Wagner - Lausanne University Hospital, Lausanne, Switzerland )
21 Feb 2025

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

Prof Joy Ho - The University of Sydney, Sydney, Australia
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies ( Prof Joy Ho - The University of Sydney, Sydney, Australia )
28 Oct 2024

ESMO 2024: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )
16 Sep 2024

Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients

Dr Do-Youn Oh - Seoul National University Hospital, Seoul, Korea
Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients ( Dr Do-Youn Oh - Seoul National University Hospital, Seoul, Korea )
15 Jul 2024

Immunotherapy significantly increases the number of patients free from bowel cancer

Dr Kai-Keen Shiu - UCL Cancer Institute, London, UK
Immunotherapy significantly increases the number of patients free from bowel cancer ( Dr Kai-Keen Shiu - UCL Cancer Institute, London, UK )
14 Jun 2024

ESMO 2023: Highlights and analysis

Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2023: Highlights and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
8 Nov 2023

Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC

Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of the EORTC Gastric Cancer Task Force
Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC ( Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of the EORTC Gastric Cancer Task Force )
6 Jul 2023

Cetuximab with XELOX or XELIRI is tolerable and effective in RAS wild-type mCRC

Dr Jamal Zekri - King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
Cetuximab with XELOX or XELIRI is tolerable and effective in RAS wild-type mCRC ( Dr Jamal Zekri - King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia )
27 Apr 2023

Latest treatments in oesophageal cancer

Dr Costas Bizekis - NYU Langone Perlmutter Cancer Center, New York, USA
Latest treatments in oesophageal cancer ( Dr Costas Bizekis - NYU Langone Perlmutter Cancer Center, New York, USA )
5 Apr 2023

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation